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type 2
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Abstract
Background: Charcot-Marie-Tooth (CMT) disease is one of the most common hereditary peripheral neuropathy.
The major clinical features of CMT are progressive muscle weakness of distal extremities and sensory loss. MFN2
encodes a GTPase dynamin-like protein mitofusin 2 and plays an essential role in mitochondrial functions. In
previous studies, MFN2 mutations have been linked to neurological disorders including CMT type 2 (CMT2). Here,
we report a novel mutation in MFN2 which leads to CMT 2.
Case presentation: We report a 4-year-old Chinese boy with CMT symptoms including foot-drop gait, running
difficulties, frequent falls, slowly progressive atrophy of lower legs with a mildly foot deformity. Nerve conduction
velocity study (NCVS) found that no compound motor action potential (CMAP) was elicited in the nervi suralis and
tibial nerve. Moreover, the sensory nerve action potential (SNAP) of the nervi suralis was not elicited, which means
the peripheral nerves of his lower limbs were damaged. Targeted next-generation sequencing identified a novel
heterozygous mutation c.730G > C (p.Val244Leu) in MFN2 in the patient but not in his parents, suggesting that this
mutation likely occurred de novo. c.730G > C (p.Val244Leu) in MFN2 is a likely pathogenic mutation for CMT2.
Conclusion: The c.730G > C (p.Val244Leu) mutation in MFN2 is a likely pathogenic mutation for CMT2.
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Background
Charcot-Marie-Tooth (CMT) disease, also known as her-
editary motor sensory neuropathy (HMSN),is one of the
most common hereditary peripheral neuropathy with an
estimated prevalence of 1 in 2500 [1, 2]. The major clin-
ical features of CMT are progressive muscle weakness of
distal extremities and sensory loss [3]. According to the
clinical symptoms and electrophysiological characteris-
tics, CMT is categorized into type 1 (CMT1) and type 2
(CMT2) [4]. CMT1 is characterized by hypertrophic
demyelination with slow nerve conduction velocities
(NCVs) (median nerve conduction velocity <38 m/s),
while CMT2 is characterized by normal or mildly reduced
NCVs (median nerve conduction velocity >38 m/s) along
with axonopathy [1, 4].
MFN2 is located on the short arm of chromosome 1
and encodes mitofusin 2, a GTPase dynamin-like protein
of the outer mitochondrial membrane. It plays an essen-
tial role in mitochondrial functions including fusion,
axonal transport, interoranellar communication and
mitophagy [5, 6]. In previous studies, MFN2 mutations
have been linked to neurological disorders including
CMT2 (named as CMT2A2, OMIM#609260). To date,
more than 100 MFN2 mutations have been reported to
be associated with CMT2 [6, 7]. Among them, there is
just one mutation at the 730th nucleotide in the encod-
ing region (c.730G > A/p.Val244Met) [8].
Here, we reported a 4 year-old-boy with CMT2 symp-
toms including muscle weakness, difficulty in running
and frequent fall. Targeted next-generation sequencing
identified a novel heterozygous mutation c.730G > C
(p.Val244Leu) in MFN2, which occurred de novo.
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Case presentation
The patient was a 4-year-old Chinese boy who couldn’t
stand steadily by himself and had suspicious foot-drop
gait. Physical examination revealed atrophy of lower ex-
tremities (Fig. 1). His left foot showed a mild pescavus
deformity and could not lift up by himself. There was no
strength in his right hand. Testing of the deep-tendon
reflexes showed reduced patellar tendon reflex and ankle
reflex. There were no Babinski sign, Chaddock sign,
Oppenheim sign and Gordon sign. Muscle strength was
reduced with MRC scores of IV on lower extremities.
The muscular tension was mildly reduced. NCVS
showed damage of peripheral nerves.
The patient is the third child in his family. His two sis-
ters who are four and two years older were completely
healthy. No family history of similar problems was pre-
sented. The patient was one of the two twins when his
mother was in pregnancy. Unfortunately his twin
brother died in the uterus. Since his mother’s amniotic
fluid broke early, he was born by caesarean with 5.73
pounds in weight. There was no asphyxia at birth. During
his growing progress, he could walk at the age of 1 year
and 7 to 8 months albeit not steadily with suspicious foot-
drop gait. He was easy to fall when running with progres-
sive aggravation. He had normal intelligence. NCVS
showed normal motor nerve conduction velocity (MCV)
of upper limbs but showed slower sensory nerve conduc-
tion velocity (SCV). In addition, neither compound motor
action potential (CMAP) or sensory nerve action potential
(SNAP) of lower limbs was elicited, indicating that the
peripheral nerves of his lower limbs were damaged
(Tables 1 and 2). When it comes to brain and spinal
MRI, the brain MRI image indicates the possibility of
periventricular leukomalacia (PVL) while the spinal
MRI image shows no apparent abnormality (Fig. 2). As for
lumbar puncture, the cerebrospinal fluid examination
Fig. 1 The lower extremities of the patient
Table 1 NCVS results (motor nerve conduction velocity)
Nerve Stimulation site Recording site Latency (mS) & amplitude (mV) Conduction
velocity (m/s)
F wave
Proximal muscle Distal muscle
(mS) (mV) (mS) (mV) mS Occurrence
rate
Right median nerve Elbow wrist Abductor pollicis
brevis
4 6.3 2 6.7 50
Right ulnar nerve Elbow wrist Abductor digiti
quinti
3.7 4.7 1.83 4.7 53.5
Right tibial nerve Popliteal fossa ankle Abductor hallucis
muscle
10.8 0.3 Not elicited Not elicited
Left tibial nerve Popliteal fossa ankle Abductor hallucis
muscle
10.7 0.02 5.5 0.02 29.8 Not elicited
Right common peroneal
nerve
Popliteal ankle Extensor brevis
digitorum
Not elicited Not elicited
Left common peroneal
nerve
Popliteal ankle Extensor brevis
digitorum
Not elicited Not elicited
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results were normal. The leucocyte count was zero,
the protein and sugar quantifications were in normal
control range and the immunoglobulin quantifications
were as well.
Since the clinical features of the patient was suspi-
cious of CMT, we sequenced 133 candidate genes for
hereditary motor sensory neuropathy (HMSN) and
identified a novel heterozygous mutation c.730G > C
(p.Val244Leu) in MFN2. This mutation was not present
in either of his parents.
Discussion
MFN2 is located on the short arm of chromosome 1. It
encodes mitofusin 2, a GTPase dynamin-like protein of
the outer mitochondria membrane.MFN2 has an essential
role in mitochondrial functions including fusion, axonal
transport, interorganellar communication and mitophagy
[5, 6]. Because mitochondria are crucial organelles present
in almost all cells of human body (except erythrocyte) to
provide ATP for metabolic processes and oxidative phos-
phorylation [9], mutations of MFN2 may cause mitochon-
dria dysfunction and affect high energetic demand tissues.
Since the first heterozygous mutation in the MFN2 has
been found by Züchner et al in 2004, more than 100
MFN2 mutations have been reported to be associated with
CMT [6, 7, 10]. Based on the existing reports, these muta-
tions can be either gain or loss of function in mito-
chondria. In some cases, certain MFN2 mutations are
associated with specific clinical features [11]. c.730G >
A (p.Val244Met), a mutation occurring at the same
position as the one reported in this study, has been re-
ported to cause CMT2 by K.Kijima et al in 2005. The
Japanese kid with the c.730G > A mutation showed
CMT2 phenotype with no sensory impairments. The
age of onset was 10 months and the symptom included
walking difficulties [8]. In our study, the patient’s symp-
tom at the onset was abnormal gait when he started to
walk at the age of 1 year and 7 to 8 months. Then he
showed running difficulties, frequent falls and slowly
progressive atrophy of lower legs with a mild deformity
at his left foot. On the other side, this boy did have sen-
sory loss at his lower limbs. All of these symptoms
agree with CMT phenotypes. Because of his median
nerve conduction velocity is 50.0 m/s (>38 m/s), we
classified it as CMT2.
Based on previously reports and the clinical symp-
toms of the patient, we believe that the novel MFN2
mutation identified in this study has a deleterious na-
ture and is the likely cause of CMT2 for the follow-
ing reasons:. First, the c.730G > C mutation changes
an amino acid from valine to leucine and may affect
protein features. Second, p.Val244Leu in MFN2 was
predicted to be disease-causing by all three computa-
tional tools (Mutation Taster, PROVEAN and SIFT).
Third, this mutation changed an evolutionarily con-
served amino acid (Phylop score is 5.51) (Table 3).
Four, according to previous reports, there is one CMT2A
disease causing mutation at the same position (c.730G >
A/p.Val244Met). In summary, the de novo pattern is con-
sistent with the previously reported autosomal dominant
inheritance of CMT2A2.
Conclusion
The c.730G > C (p.Val244Leu) mutation in MFN2 is a
likely pathogenic mutation for CMT2.
Ethics approval and consent to participate
Written informed consent was obtained from the par-
ents of the patient for participate with ethics approval.
Table 2 NCVS results (sensory nerve conduction velocity)
Nerve Stimulation site Recording site Latency (mS) Amplitude (uV) Conduction velocity (m/s)
Right median nerve Index finger Wrist 5.8 5.9 15.5
Right ulnar nerve Little finger Wrist 2 42 40
Right nervi suralis Crus Ankle Not elicited
Left nervi suralis Crus Ankle Not elicited
Fig. 2 The brain MRI image of the patient
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Consent to publish
Written informed consent was obtained from the par-
ents of the patient for publication of this case report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
Availability of data and materials
The main data that supported the conclusion of the
manuscript are presented in the paper and additional
supporting files.
Endnotes
The endnotes we used were reference and included in
the reference section.
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